Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adalimumab trough concentration-guided dose reduction in rheumatoid arthritis
NL-OMON24020Recruiting
- Sponsor
- Reade Rheumatology Research Institute
- Start
- Dec 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Randomised, open-label trial of adalimumab in rheumatoid arthritis (RA) (2 arms), sponsored by Reade Rheumatology Research Institute. Primary endpoint: Disease activity after dose reduction. Started Dec 2019; status: recruiting.
02
Drugs
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NL-OMON24020.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON24020.